Please login to the form below
beta thalassaemia
This page shows the latest beta thalassaemia news and features for those working in and with pharma, biotech and healthcare.
Vertex to lead development of CRISPR Therapeutics-partnered gene therapy
According to the companies, seven patients with transfusion-dependent beta thalassaemia (TDT), including three who have either a severe or b0/b0 genotype, were transfusion independent at the last follow-up.
Latest news
-
bluebird bio anticipates lift of clinical holds on LentiGlobin in mid-2021
210 clinical studies of LentiGlobin for SCD, as well as the holds on the HGB-207 and HGB-212 studies of beti-cel for beta-thalassaemia. ... In relation to its beta-thalassaemia gene therapy Zynteglo, bluebird bio said this would be withdrawn from the
-
Vertex gains FDA fast track designation for diabetes stem cell therapy
This includes CTX001 – an investigational gene therapy – which has already demonstrated promising early data in transfusion-dependant beta thalassaemia (TDT) and severe sickle cell disease (SCD) patients.
-
bluebird bio says AML case "very unlikely" to be related to gene therapy LentiGlobin
the FDA that we believe these results support lifting the clinical holds on our beta-thalassemia and sickle cell disease programmes,” he added. ... bluebird bio said that, based on the available data, it has initiated discussions with regulators to
-
bluebird bio posts modest Q4 revenue growth as it continues investigation into troubled LentiGlobin
In addition to the clinical holds, bluebird has also temporarily paused marketing of the gene therapy in Europe, where it is currently marketed as Zynteglo for the treatment of beta thalassaemia. ... Zynteglo was initially approved in the EU in 2019,
-
NICE turns down bluebird bio’s gene therapy Zynteglo
The UK’s National Institute for Health and Care Excellence (NICE) has rejected bluebird bio’s gene therapy Zynteglo for patients with transfusion-dependent beta-thalassaemia (TDT) in draft guidance. ... The one-off gene therapy was approved by the
bluebird bio anticipates lift of clinical holds on LentiGlobin in mid-2021
Vertex gains FDA fast track designation for diabetes stem cell therapy
More from news
Approximately 7 fully matching, plus 25 partially matching documents found.
Latest Intelligence
-
Case-study for thalassaemia: Dimitri Azzopardi
An in-depth look at beta thalassaemia for Rare Disease Day. Beta thalassaemia major is a serious, lifelong genetic blood disorder. ... At least 75, 000 children are born. with thalassaemia worldwide every year, of which 10, 000 have the debilitating form
-
20 for 2020 – Five pharma companies to watch
treatment ozanimod and myelodysplastic syndromes/beta thalassaemia candidate luspatercept – to deliver on their potential.
Case-study for thalassaemia: Dimitri Azzopardi
20 for 2020 – Five pharma companies to watch
More from intelligence
Approximately 0 fully matching, plus 2 partially matching documents found.
COVID-19 Updates and Daily News
Featured jobs
- Account Manager - Healthcare Consultancy
-
Salary depending on experience
- Project Director, Healthcare Marketing Agency patient focus Lond...
-
Highly competitive salary
-
Midweight-Senior Creative
-
Competitive Salary Offered
- Principal/ Senior/ Medical Writer – Global Med Ed and Comms Agen...
-
Highly competitive salary
- Digital Project Director, Healthcare Marketing Agency patient fo...
-
Highly competitive salary
- Senior Consultant, Pricing & Market Access Consultancy, circ...
-
circa £100K package
-
Events Executive
-
Depending on Experience
-
Digital account director
-
Competitive
- One dose of AZ’s COVID-19 vaccine ‘highly effective’ against severe disease from variants
- AZ publishes new real-world safety data for COVID-19 vaccine Vaxzevria
- Mixing AZ and Pfizer COVID-19 vaccines increases antibody levels
- Understanding the ‘real world’ starts and ends with the patient
- Michael J. Fox Foundation and IBM reveal new AI model for Parkinson’s disease
- Biogen and Eisai present new data for controversial Alzheimer's drug Aduhelm at AAIC
- CONGREGO™ IS NOW MULTI-PLATFORM
- Onyx Health Marks Record Growth with Six New Appointments
- FDA expands use of COVID-19 antibody cocktail
- New European supply deals show Pfizer and Moderna have increased COVID-19 vaccine prices
- Ipsen’s spending spree bolsters neurology pipeline
- AMICULUM® launches Cence, a new specialist publications agency
- The future of office working designed with our people in mind: ‘Work Where You Work Best’, an Evoke KYNE model
- GSK, Vir’s sotrovimab cuts hospitalisation and death risk by 79% in COVID-19 outpatients
- Biogen and Ionis post ‘encouraging’ early results for Alzheimer’s disease candidate
- Eylea set to challenge Lucentis in UK after NICE recommendation
- Onyx Health Launch Creative Studio After Record Year
- BioNTech to use mRNA technology to develop a ‘highly effective’ malaria vaccine
PMHub
W2O Group
W2O Group is an integrated marketing agency with expertise in brand and digital strategy, creative development and communications services. We...
Latest intelligence
- Guide
- How to embrace behavioural science principles in healthcare MR...
- Top 10 ways to leverage the Impetus InSite Platform® to (virtually) launch your brand
- The Impetus InSite Platform® can be used to facilitate virtual and hybrid engagement at all stages of the product lifecycle. Here, we share 10 of the most popular ways to...
- Employee wellbeing in creative agencies: three tips to get you started
- Paul Hutchings, founder of fox&cat, and new friend, Welfy, a workplace wellbeing training firm, discuss the importance of collaboration...
